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A B S T R A C T
Obesity is a significant contributor to increased morbidity and premature mortality due to increasing the risk of
many chronic metabolic diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer.
Lifestyle modifications such as energy restriction and increased physical activity are highly effective first-line
treatment strategies used in the management of obesity. However, adherence to these behavioral changes is
poor, with an increased reliance on synthetic drugs, which unfortunately are plagued by adverse effects. The
identification of new and safer anti-obesity agents is thus of significant interest. In recent years, plants and their
phenolic constituents have attracted increased attention due to their health-promoting properties. Amongst
these, Cyclopia, an endemic South African plant commonly consumed as a herbal tea (honeybush), has been
shown to possess modulating properties against oxidative stress, hyperglycemia, and obesity. Likewise, several
studies have reported that some of the major phenolic compounds present in Cyclopia spp. exhibit anti-obesity
effects, particularly by targeting adipose tissue. These phenolic compounds belong to the xanthone, flavonoid
and benzophenone classes. The aim of this review is to assess the potential of Cyclopia extracts as an anti-obesity
nutraceutical as underpinned by in vitro and in vivo studies and the underlying cellular mechanisms and bio-
logical pathways regulated by their phenolic compounds.
1. Introduction
The prevalence of obesity has steadily increased in recent decades,
with current estimates reporting that approximately 8.9% of the world’s
population (641 million individuals) are classified as obese with a body
mass index (BMI) ≥ 30 kg/m2 [1]. Obesity is regarded as the largest
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modifiable risk factor for chronic diseases such as type 2 diabetes
(T2D), cardiovascular diseases (CVD) and certain types of cancers [2,3].
Although historically considered a disease of affluence, obesity rates are
rapidly increasing in low-and middle-income countries, thus placing a
major burden on already struggling and over-burdened health systems
[4–6]. While innate biological mechanisms may predispose to obesity,
lifestyle factors, which include the consumption of unhealthy, energy-
dense diets and limited physical activity, are arguably the main de-
terminants of the current obesity pandemic [4,7], and the focus of first-
line anti-obesity strategies, including calorie-restrictive diet and in-
creased physical exercise. However, adherence to behavioral changes
are poor, with an increased reliance on synthetic drugs, which are
plagued by adverse effects [8,9]. Thus, the identification of new and
safer anti-obesity agents is of significant interest. In recent years, plants
and their phenolic compounds have attracted increased attention due to
their perceived health-promoting properties. Natural products are
usually considered safer and more socially acceptable than conven-
tional drugs, and in the case of food, consumed as part of the diet.
Amongst these, extracts of Cyclopia, an endemic South African plant
commonly consumed as a herbal tea (honeybush), has been shown to
possess ameliorative properties against oxidative stress, inflammation,
hyperglycemia, and obesity [10–18]. Likewise, a number of studies
have reported that major phenolic compounds present in Cyclopia spp.
exhibit anti-obesity effects [19–24].
This review provides a comprehensive summary of all published in
vitro and in vivo studies that have reported on the ameliorative prop-
erties of the major phenolic groups (xanthones, flavonoids and benzo-
phenones) and extracts of Cyclopia spp. against obesity. Three data-
bases, PubMed, Scopus and Web of Science, were searched for studies
published between January 2000 and March 2019, and reporting on the
anti-obesity effects of the major phenolic compounds and extracts of
Cyclopia in adipocytes. Keywords included Cyclopia, xanthone, flavo-
noid, benzophenone, obesity, and adipose tissue, as well as the corre-
sponding synonyms and associated terms for each word (Table S1).
2. Adipose tissue as a therapeutic target
Obesity is characterized by the excessive expansion of white adipose
tissue [25], which occurs by either hyperplasia (increase in adipocyte
number) or hypertrophy (increase in adipocyte size) [26]. Adipocyte
hyperplasia is considered a mechanism for healthy storage of excess
energy as triglycerides and releasing of energy as free fatty acids (FFA)
during energy deprivation [27]. Adipocyte hypertrophy is associated
with hypoxia, fibrosis, oxidative stress, endoplasmic reticulum stress,
insulin resistance and adipocyte dysfunction (Fig. 1) [28]. In addition,
adipocyte hypertrophy induces cell death and inflammation due to the
infiltration of M1 pro-inflammatory macrophages into adipose tissue
[28–31]. Adipocyte dysfunction and inflammation are considered the
primary mechanisms linking obesity to metabolic disease [32–35]
(Fig. 1). Dysfunctional adipocytes secrete high levels of FFA and pro-
inflammatory cytokines into the circulation, inducing insulin resistance
and inflammation in peripheral tissues such as the liver, muscle, pan-
creas, heart and brain (Fig. 1). Similar to adipose tissue, increased levels
of FFA and pro-inflammatory cytokines induce the recruitment of im-
mune cells in these tissues and subsequently induce chronic in-
flammatory responses (Fig. 1) [36]. High levels of FFA and pro-in-
flammatory cytokines, mainly tumor necrosis factor alpha (TNF-α) and
interleukin 6 (IL-6), induce insulin resistance in peripheral tissues such
as the muscle and liver by directly inhibiting the insulin receptor sub-
strate 1 (IRS-1) signaling or through the activation of inflammatory
kinases that inhibit insulin signaling pathways [34]. Furthermore, in-
creased concentrations of circulatory FFA result in ectopic fat deposi-
tion in peripheral tissues and increase the production of toxic lipid
metabolites such as ceramides, that increases oxidative stress and me-
tabolic dysfunction (Fig. 1) [34].
Increasing evidence highlight the association between copper
homeostasis and lipid metabolism [37], with altered copper bioavai-
labity shown to predict early atherosclerosis, suggesting that copper
bioavailability is a potential biomarker for future cardiovascular risk
assessment in obese patients with hepatic steatosis [38]. Copper is an
essential element for most living organisms and plays a vital role in
numerous cellular and physiological functions [39,40]. In adipocytes,
copper is essential for mitochondrial respiration and protection against
oxygen radicals, and its deficiency is associated with increased fat de-
position and adipocyte hypertrophy, mainly as a result of altered pro-
cessing of metabolic fuels by adipocytes (Fig. 1) [39]. Hence copper
bioavailability may be one of the mechanisms inducing adipocyte
dysfunction during obesity.
Alterations in gut microbiota play an important role in the devel-
opment of obesity, and thus the modulation of gut microbiota and
microbiota-host interaction could present a promising therapeutic
strategy to prevent obesity and obesity-associated complications [41].
Although the pathological events that link altered gut microbiota to
obesity are poorly understood, studies have suggested that obesity is
associated with the increased translocation of bacteria and bacterial
products such as lipopolysaccharides (LPS) into the bloodstream
through enhanced intestinal permeability (“leaky gut syndrome”)
caused by reduced tight junction expression [42]. Their absorption
triggers inflammation by increasing the infiltration of immune cells in
adipose tissue and altering adipocytokine production, thus identifying
adipose tissue as one of the major targets of gut microbiota derived
metabolites [42]. Intestinal bacteria also produce short-chain fatty
acids such as butyrate and phenolic acids such as protocatechuic acid,
with anti-inflammatory and anti-lipolytic effects, and the ability to
suppress fat storage [43–45]. Targeting adipocyte dysfunction thus
presents an ideal strategy to treat obesity and prevent adverse sys-
tematic effects and the negative effects of obesity on peripheral tissue.
3. Current and emerging therapeutic strategies for obesity
The first-line of treatment for obese individuals is lifestyle mod-
ification, with dietary changes towards calorie restriction, and in-
creased physical exercise as the cornerstone (Table 1) [7]. Pharma-
cotherapy is prescribed for individuals who are unable to control
obesity with lifestyle modifications or as an adjunct in overweight or
obese individuals with obesity-related comorbidities [46]. Orlistat
(PubChem CID: 3034010), approved since 1999 by the Food and Drug
Administration (FDA) for the long-term treatment and management of
obesity [8,47], inhibits pancreatic lipase activity and fat absorption in
the intestine, promoting fecal fat excretion (Table 1) [48,49]. Un-
fortunately, Orlistat induces several gastrointestinal side-effects such as
oily stools, flatulence, increased defecation, and interferes with nutrient
and drug absorption [8,50,51]. Over the last decade new pharmacolo-
gical drugs, including lorcaserin (PubChem CID: 11658860), phenter-
mine/topiramate (PubChem CID: 9848354), phentermine (PubChem
CID: 4771), naltrexone/bupropion (PubChem CID: 11556075) and lir-
aglutide (PubChem CID: 16134956) have been approved by the FDA
and are currently used for short-term and long-term obesity treatment
(Table 1) [8,47]. These drugs act by suppressing appetite or promoting
satiety through activation of the serotonin (5-HT2c) receptor, stimu-
lating the release of noradrenalin, inhibiting dopamine and nor-
epinephrine re-uptake, and stimulating the glucagon-like peptide 1
(GLP-1) receptor (Table 1) [9]. Despite their weight-loss efficacy, ad-
verse effects including headaches, insomnia, cardiovascular complica-
tions and psychiatric disorders are associated with weight-loss drugs, to
the extent that several anti-obesity drugs, such as sibutramine (Pub-
Chem CID: 5210), rimonabant (PubChem CID: 104850) or fen-
fluramine/phentermine (PubChem CID: 9821243), have been with-
drawn from the market [8,9,52,53].
Several new drugs or drug combination therapies are in the pipeline
or undergoing clinical phase development and may be approved for
obesity treatment in the next few years [52]. These potential drugs
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target the central nervous system, the gastrointestinal tract, as well as
various hallmarks of adipocyte dysfunction as described previously
[54]. Targeting energy expenditure, particularly adaptive thermogen-
esis, is now recognized as an attractive alternative approach for obesity
treatment [55]. Browning of white adipose tissue (inducing beige adi-
pocytes), or stimulation of thermogenesis in brown adipose tissue have
attracted considerable interest as anti-obesity strategies [56,57]. Sev-
eral compounds that are currently being investigated for their anti-
obesity potential, have been reported to induce browning of white
adipose tissue or to activate thermogenesis in brown adipose tissue.
Beta-3 adrenergic receptor (β3-AR) agonist compounds, such as
CL316243 (5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]
amino]propyl]-1,3-benzodioxole-2,2-dicarboxylic acid, disodium salt)
(PubChem CID: 5312115) and mirabegron (PubChem CID: 9865528),
activate brown adipose tissue and thermogenesis, induce beige adipose
tissue in subcutaneous white adipose tissue, and increase energy ex-
penditure and resting metabolic rate in rodents and humans [58–62],
demonstrating their potential as anti-obesity agents [62]. Despite the
availability of various anti-obesity therapeutics, there is still a lack of
effective anti-obesity therapies with negligible side effects. Plant-de-
rived natural products such as phenolic compounds are attracting in-
creasing interest as therapeutic agents due to the perception that they
are safer and more cost-effective than synthetic drugs [63]. Phenolic
compounds have been shown to modulate the physiological and mo-
lecular pathways regulating adiposity, potentially reversing obesity and
obesity-related metabolic disease [64,65]. Furthermore, a recent study
reported that supplementation of a high-fat/high-sucrose diet with a
polyphenol-rich plant extract prevented adipose tissue dysfunction by
reducing macrophage recruitment and the accumulation of endotoxins,
cholesterol and cholesterol oxides in adipose tissue, thus increasing the
lifespan of mice irrespective of their reduced body weight [66]. This
suggest that adipose tissue is an important therapeutic target for ame-
liorating obesity-associated metabolic disorders and increasing the life
span of obese subjects.
Fig. 1. Adipose tissue dysfunction and systemic effects on peripheral tissues. Adipocytes within healthy normal adipose tissue are infiltrated by M2 macrophages and
store excessive energy as triglycerides and release the energy as FFA during energy deprivation. Obesity often leads to adipocyte hypertrophy, which is associated
with hypoxia, increased basal levels of lipolysis, oxidative and endoplasmic reticulum stress, fibrosis, adipocyte cell death, recruitment and infiltration of M1
macrophages, chronic inflammation and insulin resistance within adipocytes. This leads to adipose tissue dysfunction which induces excessive secretion of FFA by
lipolysis and pro-inflammatory cytokines into the circulation and to key peripheral tissues such as the liver, muscle, pancreas, heart and the brain. High levels of FFA
lead to ectopic fat deposition and lipotoxicity in tissues such as liver, pancreas and muscle, while pro-inflammatory cytokines induce systemic low-grade chronic
inflammation in the liver, muscle, pancreas, heart and the brain, thus leading to metabolic dysfunction of these tissues and the development of obesity-related
diseases.
Figure abbreviations: ER, endoplasmic reticulum; FFA, free fatty acids; IFN-γ, interferon gamma; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-10, interleukin 10;
MCP-1, monocyte chemoattractant protein 1; TNF-α, tumour necrosis factor alpha.
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4. Cyclopia spp.
Species from the genus Cyclopia Vent. (Family: Fabaceae; Tribe:
Podalrieae), also referred to as honeybush, have a long history of use as
herbal tea [67]. Of the 23 species described thus far [68], C. subternata,
C. genistoides, C. intermedia, C. maculata, C. longifolia and C. sessiliflora
are currently used commercially to a greater or lesser extent for tea
production [69]. Honeybush tea has gained popularity due to its dis-
tinctively sweet flavour, aroma, and caffeine-free status, as well as low
tannin content compared to black teas [69,70]. The “fermented” (oxi-
dized) form is mostly produced for herbal tea consumption, while the
“unfermented” (green) product with higher polyphenol content and
anti-oxidant activity was initially developed as source material for
production of nutraceutical extracts [69], but in recent years, a small
quantity is also consumed as herbal tea. The global demand for hon-
eybush tea has increased significantly over the last few years, partially
attributed to its perceived beneficial health properties. Mounting sci-
entific evidence demonstrates that extracts of Cyclopia spp. exhibit
potential anti-diabetic [10,15], anti-oxidant [12,18], anti-mutagenic
[71], anti-cancer [72], phytoestrogenic [73], anti-osteoclastogenic
[74], anti-allergic [75] and anti-inflammatory [18] activities, in in vitro
and in vivo models. Amongst the many phenolic compounds present in
Cyclopia spp., high quantities of the xanthones, mangiferin (PubChem
CID: 5281647) and its isomer, isomangiferin (PubChem CID: 5318597),
the flavanone, hesperidin (PubChem CID: 10621), as well as benzo-
phenone glucosides and dihydrochalcone glycosides have been detected
[76]. While some of phenolic compounds have beneficial health effects
including anti-obesity potential, few studies have reported that extracts
of Cyclopia spp. exhibit anti-obesity effects [13,14,16,17], prompting
investigations into their potential as nutraceuticals for the management
of obesity.
4.1. Anti-obesity properties of Cyclopia extracts
Anti-obesity properties of Cyclopia was first reported in 3T3-L1
adipocytes, the most commonly used in vitro adipocyte cell model [77].
Dudhia et al. [13] demonstrated that an aqueous extract of “fermented”
C. maculata and aqueous extracts of “unfermented” C. maculata and C.
subternata dose-dependently inhibited adipogenesis, lipid accumula-
tion, triglyceride content and peroxisome proliferator-activated re-
ceptor gamma (PPARγ) expression in differentiating 3T3-L1 pre-adi-
pocytes. The aqueous extract of “fermented” C. maculata also
stimulated lipolysis, and increased hormone sensitive lipase (HSL) and
perilipin expression in mature 3T3-L1 adipocyte [14]. Recently, we
reported that C. intermedia demonstrated anti-obesity potential in vitro
and in vivo [16]. A crude polyphenol-enriched organic fraction of
“unfermented” C. intermedia decreased lipid content, and increased Hsl
and uncoupling protein 3 (Ucp3) gene expression in 3T3-L1 adipocytes
[16]. Furthermore, the extract decreased body weight gain in obese
leptin receptor deficient (Leprdb/db) mice [16]. To our knowledge, these
are the only experiments that have reported on the anti-obesity prop-
erties of Cyclopia extracts. However, several studies have described the
anti-obesity properties of compounds, in particular mangiferin and
hesperidin [78–81], that are also present in relative abundance in Cy-
clopia spp. Assessment of their anti-obesity effects based on the existing
body of knowledge could guide further studies aimed at enhancing
potency and efficacy of Cyclopia extracts, underpinning nutraceutical
product development.
5. Anti-obesity properties of the major Cyclopia polyphenols
5.1. Xanthones
Xanthones are classified into six main groups, the simple xanthones,
prenylated xanthones, xanthonolignoids, bisxanthones, miscellaneous
xanthones and xanthone glycosides (C- or O-glycosides) [82]. The two
most common C-glucosyl xanthones, mangiferin and its structural
isomer, isomangiferin, are present in relative high quantities in Cyclopia
spp. [76], particularly in C. genistoides and C. longifolia [83]. The glu-
cose moiety of these xanthones is attached to 1,3,6,7-tetrahydroxy-9H-
xanthen-9-one via a CeC bond at position 2 and 4, respectively. Man-
giferin is abundant in plants such as Mangifera indica (mango), Salacia
reticulata, Anemarrhena asphodeloides (bunge rhizome), Mangifera per-
siciformis (peach mango), Curcuma amada (mango ginger) and Swertia
Table 1
Overview of obesity therapeutic strategies.
Treatment Strategy Therapy Mechanism/Activity References
Lifestyle modification Diet Prevents excessive fat accumulation [7,273,274,275,276,277,278,279]
Physical activity Increases metabolic rate [274,275,276,277,280,281,282,283,284]
Pharmacological drugs Orlistata (Xenical, Alli) Reduces fat absorption (pancreatic lipase inhibition) [8,9,47,285,286,287]
Lorcaserina (Belviq) Appetite suppressant and promotes satiety (5-HT2c
receptor agonist)
Phentermine/topiramate ERa (Qsymia) Appetite suppressant (noradrenalin releaser and anti-
convulsant/neurostabilizer)
Phentermine HClb (Adipex, Lomaira) Appetite suppressant (noradrenalin releaser/
sympaticomimetic)
Naltrexone SR/buproprion SRa (Contrave) Appetite suppressant (norepinephrine/dopamine re-
uptake inhibitor and opioid receptor antagonist)
Liraglutidea (Saxenda) Appetite suppressant (GLP-1 receptor agonist)
Weight-loss surgery/
Bariatric surgeryc
Gastric sleeve; Adjustable gastric band; Roux-en-Y
gastric bypass; Biliopancreatic diversion with
duodenal switch
Restricts food intake and reduces nutrient absorption
by decreasing stomach size or changing the anatomy
of gastrointestinal area; Appetite suppression due to
physiological or hormonal changes; Increases energy
expenditure
[288,289,290,291]
Adipose physiology Browning/beiging of white adipose tissue (using
phenolic compounds such as resveratrol,
naringenin, quercetin)d; Inducing thermogenesis
(using β3-AR agonists, Exendin-4, Secretin)d
Increases energy expenditure [55,59,62,292,293,294,295,296,297]
Abbreviations: 5-HT2c, serotonin receptor; β3-AR, beta-3 adrenergic receptor; ER, extended release; HCl, hydrochloride; SR, sustained release; GLP-1, glucagon-like
peptide 1; FDA, Food and Drug Administration.
a Approved by FDA for long-term use.
b Approved by FDA only for short term use (≤ 12 weeks) and low dose.
c Only recommended for morbidly obese (BMI ≥ 40 kg/m2).
d Compounds currently being investigated or under development.
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ciliata [19,20]. Various in vitro and in vivo studies have reported on the
anti-obesity effects of mangiferin (Tables 2 and 3). Mangiferin stimu-
lated lipolysis in rat epididymal derived adipocytes [84], inhibited
adipogenesis and lipid accumulation in human mesenchymal stem cells
(hMSCs) [80] and ameliorated inflammation and insulin resistance in
hypoxic 3T3-L1 adipocytes (Table 2) [85]. In vivo, mangiferin decreased
body weight and visceral adiposity, and improved hyperlipidemia by
decreasing circulating levels of triglycerides, total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C) and FFA in high-fat diet
(HFD) and high-fructose diet (HFrD) fed rodents (Table 3) [78,86–90].
Visceral adiposity positively correlates with LDL-C levels and choles-
terol synthesis [91,92], suggesting that mangiferin targets visceral
adipose tissue to decrease FFA secretion and transport to the liver,
subsequently ameliorating hyperlipidemia by reducing the production
of LDL-C in the liver and its circulating levels, in diet-induced obese
models.
Mangiferin is also reported to stimulate adiponectin secretion in
HFD fed mice (Table 3) [87,93]. Adiponectin is an adipocyte-specific
hormone with insulin-sensitizing properties that is decreased during
obesity and hyperlipidemia [94–100]. Mangiferin also induces energy
expenditure by increasing mitochondrial oxidative capacity and ther-
mogenesis, lowers endoplasmic reticulum stress in perivascular adipose
tissue of HFD fed ICR mice, and suppresses hepatic and systematic in-
flammation in HFD fed mice [87,90,93,101–103]. Furthermore, high-
throughput metabolomic approaches (Table 3) suggest that mangiferin
ameliorates hyperlipidemia by regulating metabolic pathways such as
glycolysis, tricarboxylic acid (TCA) cycle, and lipid metabolism in HFD
fed rodents [104,105]. Our literature search identified only one human
study reporting on the anti-obesity properties of mangiferin (Table 4).
In this study, treatment of overweight and hyperlipidemic patients with
mangiferin (150 mg/kg daily for 12 weeks) decreased triglyceride and
FFA levels, and increased high-density lipoprotein cholesterol (HDL-C)
levels and lipoprotein lipase (LPL) activity [106]. In the gut, intestinal
bacteria transform mangiferin to an active aglycone metabolite, nor-
athyriol (PubChem CID: 5281656), by cleavage of the C-glucosyl bond
[107]. Norathyriol has hypoglycemic [108–110], anti-inflammatory
[111] and anti-obesity [112,113] properties. In HFD-fed mice, nor-
athyriol reversed obesity and insulin resistance by inhibiting protein
tyrosine phosphatase 1 B (PTP1B) activity [112], while suppressing
triglyceride accumulation and improving hepatic lipid metabolism
through modulating the sirtuin-1/5′ AMP-activated protein kinase/
sterol regulatory element-binding protein 1c (SIRT-1/AMPK/SREBP1c)
signaling in HepG2 human liver cells [113]. Our literature search could
not identify any studies reporting on the anti-obesity properties of
isomangiferin in both in vitro and in vivo models of obesity, although
exposure of C2C12 myocytes to isomangiferin enhanced glucose uptake
similar to mangiferin [11], demonstrating its anti-diabetic potential.
5.2. Flavonoids
Flavonoids comprise a class of polyphenols that are ubiquitous in
plants and the human diet [114–116]. Flavonoids are classified into
sub-classes, with glycosides belonging to the flavanone (hesperidin,
(2S)-5-[α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyloxy] nar-
ingenin and neoponcirin), flavone (scolymoside and vicenin-2) and
dihydrochalcone (phloretin-3′,5′-di-C-β-D-glucoside and 3-hydroxy-
phloretin-3′,5′-di-C-hexoside) classes detected in Cyclopia extracts
[117–125]. Several of the flavonoids or their aglycones have been re-
ported to exert anti-obesity properties, as discussed below.
5.2.1. Flavanones
Hesperidin (hesperetin-7-O-rutinoside) is one of the major poly-
phenols detected in Cyclopia extracts [76]. In contrast, hesperetin (4′-
methoxy-3′,5,7-trihydroxyflavanone) (PubChem CID: 72281), the
aglycone of hesperidin, has been detected in low quantities in Cyclopia
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Table 3
Summary of studies reporting on the effects of phenolic compounds of Cyclopia spp. on obesity and associated comorbidities, and the mechanism of their biological
activity in vivo in animal models of obesity.
Compound Experimental Model Dose and Treatment Period Experimental Outcomes and Proposed Mechanism References
Mangiferin High-fat diet fed male golden
Syrian hamsters
50 and 150 mg/kg BW
daily for 8 weeks
Decreased BW and reduced eWAT, pWAT and liver weights; Reduced TG and FFA levels
in serum, liver and muscle; Increased hepatic and muscle Pparα, Cd36, Cpt-1 and Lpl
gene expression; Decreased hepatic Srebp1c, Acc, Dgat2 and Mtp gene expression;
Regulated metabolic pathways involved in glycolysis, TCA cycle and lipid metabolism
[78,104]
High-fat diet fed male
hyperlipidemic Wistar and
Sprague Dawley rats
50, 100, 150 and 300 mg/
kg BW daily for 6 or 13
weeks
Reduced eWAT and hepatic fat accumulation; Decreased plasma, serum and hepatic
TG, TC, LDL-C and FFA levels; Increased plasma, serum and hepatic HDL-C and β-
hydroxybutyrate levels; Increased fecal TG and TC content; Increased phosphorylation
of AMPK and ACC in the liver; Upregulated the hepatic expression of CD36 and CPT-1;
Decreased DGAT2 expression in liver; Regulated metabolic pathways involved in TCA
cycle and glycerophospholipid metabolism
[89,105]
High-fat and high-fructose diet
fed male Wistar rats induced
with STZ
20 and 40 mg/kg BW daily
for 28 days or 6 weeks
Decreased serum and hepatic TG, TC, LDL-C, TNF-α and Hs-CRP levels; Reduced serum
and hepatic MDA content; Increased serum HDL-C and adiponectin levels
[93,303]




food) ad libitum for 16 or
18 weeks; 400 mg/kg BW
ad libitum for 16 weeks; 5
and 20 mg/kg diet ad
libitum for 12 weeks
Decreased BW gain and reduced fat and lean mass; Decreased liver weight and hepatic
steatosis; Decreased plasma TG, TC and LDL-C levels, and increased plasma HDL-C
levels; Decreased plasma IL-6 and TNF-α levels, and increased plasma IL-10 levels;
Improved glucose intolerance and insulin sensitivity; Increased plasma adiponectin
levels; Increased thermogenesis and energy expenditure; Induced muscle mitochondrial
biogenesis; Increased hepatic and muscle protein and gene expression of mitochondrial
bioenergetics genes including DHTKD1, COX6B1, Idh, α-kgdh, Sdhβ, CoxI, Cyt-c, CoxIV,




Fructose diet fed spontaneously
hypertensive and Wistar-Kyoto
male rats
5 and 15 mg/kg BW daily
for 7 weeks
Decreased plasma NEFA levels; Reduced hepatic TG and lipid accumulation; Decreased
adipose tissue insulin resistance index; Reduced hepatic DGAT2 protein expression and
reduced intracellular CD36 distribution in skeletal muscle
[304,305]
High-fat diet fed male Kunming
mice
15, 30 and 60 mg/kg BW
daily for 12 weeks
Decreased BW; Reduced serum and hepatic TG and TC levels; Suppressed inflammation
by inhibiting NF-κB and JNK pathway; Regulated autophagy and lipogenesis via
AMPK/mTOR signaling
[90]
Obese and lean phenotype
female Zucker rats
15 mg/kg BW daily for 8
weeks
Reduced BW; Decreased plasma TC, LDL-C and FGF21 levels; Reduced plasma IFN-γ, IL-
1β and IL-6 levels; Increased plasma HDL-C levels and muscle oxidative capacity
[86]
High-fat diet fed ICR male mice 50 mg/kg BW daily for 2
weeks
Suppressed ER stress, oxidative stress and inflammation in pvWAT; Increased protein
expression of LKB1, AMPK and ACC phosphorylation in pvWAT
[102]
Hesperidin C57BL/KsJ- db/db (Leprdb/db)
male mice
200 mg/kg diet for 5
weeks
Decreased plasma and hepatic FFA, TG and TC levels; Reduced hepatic β-oxidation;
Decreased hepatic FASN, CPT, ACAT and HMG-CoA reductase activities
[132]
High-cholesterol diet fed male
Wistar rats
0.08% supplemented diet
(g/g food) for 12 weeks
Decreased adipose tissue weight; Reduced liver weight and hepatic steatosis; Reduced
serum TC, lathosterol, campesterol, β-sitosterol and RBP4 levels
[79]
High-fat diet fed male Ldlr−/−
C57BL/6 JNju mice
100 and 200 mg/kg BW
daily for 12 weeks
Decreased BW gain and HOMA-IR index; Decreased serum and hepatic TC, TG, LDL-C,
ox-LDL, SOD, GPx, IL-6 and TNF-α levels; Reduced hepatic steatosis, decreased hepatic
ACCα, FASN, Il-6 and Tnf-α protein and gene expression and increased ABCG8 hepatic
protein expression; Increased hepatic SOD and GPx activity; Reduced atherosclerotic
lesion formation, increased ABCA1 and ABCG1 expression in aorta and decreased Tnf-α
gene expression in aorta
[133]
High-fat diet fed white male
albino rats induced with STZ
50 mg/kg BW daily for 4
weeks
Increased adiponectin gene expression and decreased Il-6 gene expression in adipose
tissue; Decreased serum glucose, LPO, NO, TNF-α and IL-6 levels, and increased serum
insulin and GSH levels; Decreased HbA1c and HOMA-IR index; Decreased hepatic LPO
and NO levels and increased hepatic GSH content; Increased hepatic CAT, GPx, GR and
SOD activities
[306,307]
Young (6 months) and old
(27–29 months) male C57BL/6
mice on normal, low-fat rodent
diet
0.5% supplemented diet
(g/g food) for 4 weeks
Reduced age-induced pvWAT mediated aortic stiffness and AGE accumulation;
Reversed pvWAT mediated aortic inflammation and oxidative stress
[308]
Caenorhaditis elegans (High-fat)
and (daf-2 mutant) worms
50 and 100 μM for 46 h on
standard nematode growth
medium plates
Reduced fat accumulation and the ratio of oleic acid/stearic acid; Decreased expression
of lipid metabolism genes
[137]
High-fat and high-sucrose diet
fed male Wistar rats
100 mg/kg BW daily for 8
weeks
Improved blood lipid profile; Reduced hepatic lipid accumulation and prevented liver
steatosis; Reduced adipose tissue (iWAT, rWAT, eWAT and mWAT) weights; Increased
UCP1 and CIDEA accumulation in rWAT
[309,310]
Fructose-enriched diet fed male
Wistar albino rats
5 mg/kg BW daily for 4
weeks
Decreased serum TG, TC, MDA, NO and TNF-α levels; Increased GSH serum levels;
Reduced liver steatosis
[311]
Hesperetin Orotic acid diet fed male
Sprague-Dawley rats
1% supplemented diet (g/g
food) for 10 days
Decreased hepatic TG and TC content; Reduced hepatic microsomal PAP, DGAT,
G6PDH and malic enzyme activities; Reduced serum phospholipid levels
[312]
High-cholesterol diet fed male
Sprague–Dawley rats
0.02% supplemented diet
(0.066 mmol/100 g diet)
for 5 or 6 weeks
Decreased plasma TC and TG concentrations, and plasma atherogenic index; Reduced
hepatic HMG-CoA reductase and ACAT activities; Decreased hepatic TC content
[313,314]
High-fat diet fed male golden
Syrian hamsters
[315]
(continued on next page)
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Table 3 (continued)
Compound Experimental Model Dose and Treatment Period Experimental Outcomes and Proposed Mechanism References
0.02% supplemented diet
(0.066 mmol/100 g diet)
for 12 weeks
Decreased plasma Apo B and PON levels; Reduced hepatic cholesterol, TG and H2O2
levels; Increased hepatic CAT and GR levels; Reduced hepatic HMG-CoA reductase and
ACAT activities
Chow diet fed male Wistar rats 0.5% supplemented diet
(0.0164 mmol/g diet) for 3
weeks
Decreased abdominal adipose tissue and eWAT weight; Increased fecal starch excretion
and cecal pool of short-chain fatty acids
[135]
High-fat diet fed male C57BL/
6 JOlaHsd mice
0.33% supplemented diet
(0.01 mmol/g diet) for 12
weeks
Reduced BW gain, mWAT weight and total food efficiency ratio; Reduced serum leptin
levels and eWAT leptin expression; Decreased hepatic Cyp2b9 gene expression
[134]
High-fat diet fed male Apo-E KO
mice
0.1% supplemented diet
(g/g food) for 12 weeks
Reduced plasma cholesterol levels; Decreased adipose deposition; Reduced






High-fat diet fed ICR male mice 100 mg/kg BW twice a
week for 14 weeks
Reduced abdominal adipose tissue; Decreased plasma TG, TC and LDL-C levels;





Normal diet fed ICR mice 1% supplemented diet for
21 days
Decreased serum TG, TC, FFA and phospholipid levels; Increased enzymatic activity




fed male Ldlr−/− C57BL/6 J
mice
3% supplemented diet
(wt/wt diet) for 12 and 24
weeks
Reduced BW and increased energy expenditure by increasing the RER; Reduced eWAT
size and adiposity index and decreased vWAT and ScWAT fat volume; Improved
glucose homeostasis and enhanced insulin sensitivity by reducing plasma glucose and
insulin levels; Reduced Tnf-α, Il-6, Il-1β, Ccl2, Ccl3, F4/80 and Saa1/2 gene expression
in eWAT, iWAT and BAT; Decreased plasma and hepatic TC, TG, VLDL-C, LDL-C, leptin
and SAA levels and reduced TG and apo B100 secretion; Decreased hepatic FA synthesis
and increased FA oxidation in the liver; Reduced hepatic Srebp1c, Tnf-α, Il-1β, Ccl2,
Ccl3, F4/80 and Saa1/2 gene expression; Increased hepatic Cyp7a1, Fgf21, Cpt-1,
Srebf2, Hmgcr, Pgc1α, and Acox gene expression; Decreased muscle TG content;
Prevented atherosclerosis by reducing aortic lipid accumulation, TC and TG levels and
decreasing Tnf-α, Il-1β and Ccl2 gene expression in aorta
[22,162]
Chow diet fed and low-fat chow
diet fed Ldlr−/− male C57BL/
6 J mice
3% supplemented diet
(wt/wt) for 8 weeks
Decreased BW and reduced eWAT and iWAT weights; Reduced energy expenditure;
Reduced plasma TG and TC levels and increased plasma β-hydroxybutyrate levels;
Decreased blood glucose and plasma insulin levels; Enhanced hepatic fatty acid
oxidation by increasing Pgc1α and Pnpla2 gene expression
[161]
High-fat diet fed male C57BL/
6 J wild-type and Ldlr−/− mice
1% and 3% supplemented
diet (wt/wt diet) for 4 and
30 weeks, or 6 months
Decreased BW gain and adiposity index and reduced hypertrophy in eWAT; Increased
energy expenditure and reduced lipid content in iBAT; Decreased plasma and hepatic
TG, CE, TC, leptin and insulin levels, reduced HOMA-IR index, and increased plasma
LPL activity; Reduced hepatic TG, FA, CE and TC synthesis; Reduced hepatic lipid
content and steatosis, and decreased TG and Apo B100 secretion; Increased hepatic FA
oxidation and mtDNA content; Increased hepatic Pgc1α, Cpt-1α and Aco gene
expression; Decreased hepatic and muscle gene expression of Srebp1c; Reduced TG and
TC mass in intestine and aorta
[173,174]
High-cholesterol diet fed male
Wistar and Sprague-Dawley rats
50 mg/kg BW daily for 3
months; 0.02%
supplemented diet
(0.073 mmol/100 g diet)
for 5 or 6 weeks
Decreased BW gain; Reduced plasma, hepatic and cardiac TC, TG, FFA, LDL-C and
phospholipid levels; Increased plasma HDL-C levels and reduced plasma TBARS levels;
Reduced hepatic and cardiac TBARS, LOOH and ROS levels; Reduced hepatic and
cardiac protein carbonyl content; Increased hepatic GSH, SOD, CAT and GPx levels;
Decreased hepatic and cardiac Tnf-α, Il-6, Il-1β, iNos, Emr1 and Nf-κb gene expression;
Decreased hepatic fibrosis and reduced hepatic DNA fragmentation; Reduced hepatic








(g/100 g diet) for 6 weeks
Decreased parametrial adipose tissue and TG content in parametrial adipose tissue;
Decreased liver weight; Increased hepatic PPARα, UCP2 and CPT-1 protein expression;
Decreased plasma and hepatic TG, TC and free cholesterol levels
[165]
High-fat diet fed male C57B6 J/
L mice and Wistar albino rats
50 and 100 mg/kg daily
for 28 days; 10 mg/kg BW
daily for 4 weeks; 100 mg/
kg daily for 1, 7 and 14
days; 1% supplemented
diet (g/g diet) for 16 weeks
Reduced BW, eWAT weight, and adiposity index; Decreased Tlr2, Tnf-α, Mcp-1 and
Mac-2 gene expression in eWAT, reduced protein expression of MCP-1 and JNK
phosphorylation in eWAT and reduced Mac-2 positive cells in eWAT; Increased Ucp1
and Cpt-1 gene expression in BAT; Reduced serum and plasma TG, TC, LDL-C, insulin
and glucose levels; Reduced serum TBARS levels; Increased SOD and CAT levels in
erythrocyte lysates; Decreased hepatic Fasn gene expression; Increased hepatic Cpt-1,




Caenorhaditis elegans 50 μM for 46 h on standard
nematode growth medium
plates containing Nile Red
dye
Decreased fat accumulation [317]
High-fat diet fed male C57BL6/
J wild-type and Fgf21−/− mice;
Low-fat diet fed male Lepob/ob
mice
3% supplemented diet
(wt/wt diet) for 4, 8 and
16 weeks
Decreased BW and reduced vWAT and ScWAT volume; Reduced number of adipocytes
and adipocyte hypertrophy in eWAT; Increased gene expression of Pgc1α, Cpt-1α, Lepr,
Ucp1, Atgl, Hsl, Pparα and Chrebp in eWAT; Decreased hepatic and muscle TG content;
Reduced plasma TG, leptin, insulin, glucose and TNF-α levels; Improved glucose
tolerance and inhibited insulin resistance; Decreased hepatic Srebp1c, Acc1, Acc2 and
Scd1 gene expression; Increased hepatic Pgc1α, Cpt-1α and Lepr gene expression
[157]
(continued on next page)
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Table 3 (continued)
Compound Experimental Model Dose and Treatment Period Experimental Outcomes and Proposed Mechanism References
High-fat diet fed male Wistar
albino and Sprague-Dawley rats
induced with STZ
25 mg/kg BW daily for 45
days; 50 and 100 mg/kg
BW daily for 6 weeks
Decreased BW; Reduced TNF-α adipocyte gene and protein expression; Increased
adipocyte and skeletal muscle GLUT4 gene and protein expression; Reduced serum
glucose, insulin, TG, TC, FFA, LDL-C and VLDL-C levels; Increased serum HDL-C levels;
Improved glucose tolerance; Reduced plasma, serum, liver and pancreatic TBARS and
hydroperoxide levels; Increased SOD, CAT and GPx levels
[168,169]
High-fat diet fed obese female
ovariectomized C57BL/6 J mice
1% and 3% supplemented
diet (wt/wt diet) for 5, 11
and 22 weeks
Decreased BW and calorie intake; Reduced ScWAT and intra-abdominal adiposity
(pgWAT, mWAT, mammary WAT); Reduced leptin, Il-6, Ccl2, and α-Sma gene
expression in pgWAT, ScWAT and mammary adipose tissue; Elevated locomotor
activity; Reduced plasma, muscle and hepatic glucose, insulin, TC, TG, leptin and lipid
levels; Reduced muscle diacylglycerol content and decreased HOMA-IR index;
Decreased muscle and hepatic Fasn, Scd1, Dgat2, Hsl and Acox1 gene expression;
Increased hepatic Srebf1, Cpt-1α, Pgc1α and Pck2 gene expression
[158,159,-
160]
High-fructose diet fed male
Wistar rat
50 mg/kg BW daily for 6
weeks
Suppressed insulin resistance by decreasing plasma glucose, insulin, TG and FFA levels;
Increased protein expression of SIRT1 and AMPK phosphorylation and upregulated
Pgc1α gene expression in skeletal muscle; Increased protein expression of GLUT4
translocation in skeletal muscle; Increased hepatic eNOS protein expression; Reduced
TBARS levels, lipid hydroperoxides and protein carbonyl content in plasma, liver and




High-fat and high-fructose diet
fed male Sprague−Dawley rats
2.6 mmol/kg
supplemented diet for 13
weeks
Decreased BW; Reduced vWAT, pWAT and adipocyte hypertrophy in eWAT; Decreased
serum and hepatic LDL-C, TC, TG and FFA levels; Increased serum HDL-C levels;
Reduced serum leptin, TNF-α and IL-6 levels; Decreased serum MDA content and
increased total anti-oxidant capacity level in serum
[164]
High-cholesterol diet fed male
New Zealand White rabbits
0.05% supplemented diet
for 8 weeks
Decreased fat content in the aorta; Decreased Vcam-1 and Mcp-1 gene expression in
aorta; Reduced hepatic ACAT activity
[176]
Eriocitrin High-fat and high-cholesterol




diet) for 21 days





32 mg/kg daily for 4 weeks Decreased plasma TG levels and reduced hepatic lipid content; Increased hepatic
mitochondrial β-oxidation and expression of genes involved in mitochondrial
biogenesis including Tfam, Nrf1, Cox4I1, Atp5j; Increased expression of lipid






High-fat diet fed male C57BL/
6 J mice
100 (hesperidin) and 200
(eriocitrin) mg/kg BW
daily for 4 weeks
Decreased serum glucose, TC, LDL-C, TBARS, IL-6, MCP-1 and Hs-CRP levels; Increased
serum HDL-C and ABTS levels; Reduced hepatic fat accumulation; Decreased hepatic
TBARS levels and reduced liver damage
[183]
Luteolin High-fat diet fed male C57BL/6
mice
10 mg/kg BW daily for 20
weeks; 0.002% and 0.01%
supplemented diet (g/g
diet) for 10, 12 and 20
weeks
Decreased BW and increased energy expenditure; Reduced food intake; Reduced
adipose tissue weights (eWAT, ScWAT and BAT) and decreased adipocyte hypertrophy
in eWAT; Reduced adipose tissue inflammation, decreased M1 macrophage and mast
cells infiltration in eWAT; Increased M2 macrophage infiltration in eWAT and
enhanced eWAT angiogenesis; Decreased F4/80, Mcp-1, Il-6, Tnf-α, Cd36, Plin2 and
mMCP-4 expression in eWAT; Increased AMPKα1 signaling and protein expression of
AKT phosphorylation and GLUT4 translocation in eWAT; Stimulated thermogenic and
beige cell markers (Ucp1, Pgc1α, Pparα, Cidea, Elovl3, Sirt1, Tmem26, Cd137 and Cited1
gene expression) in BAT and ScWAT; Increased protein expression of UCP1, AMPKα
and ACC phosphorylation in BAT and ScWAT; Improved glucose intolerance by
decreasing plasma and serum glucose and insulin levels; Induced insulin sensitivity and
reduced HOMA-IR index; Reduced plasma and serum TG, TC, leptin, resistin, MCP-1,
IL-6 and TNF-α levels; Increased plasma and serum adiponectin levels; Decreased TNF-
α levels and increased protein expression of SOD1 and miR-214-3p expression in
mesenteric arteries; Decreased TBARS, TNF-α and IL-1β levels in brain; Decreased Tnf-α
and Il-1β gene expression in brain and reduced NF-κB protein expression in brain;




High-fat diet fed male C57BL/
6 J and C57BL/6 N mice
0.005% supplemented diet
(wt/wt) for 16 weeks; 50
and 250 ppm
supplemented diet (g/kg
diet) for 8 weeks; 0.6%
and 1.5% supplemented
diet (wt/wt) for 3 and 57
days
Decreased BW gain and reduced adipose tissue weights (eWAT, pWAT, rWAT, mWAT,
vWAT, ScWAT and iWAT); Reduced food efficiency ratio; Increased Acc, Srebp1, Srebp2,
Cpt-1, Cpt-2, Ucp-1, Pgc1β, Cd36 and Lpl gene expression, and increased SREBP1 and
PPARγ protein expression in eWAT; Reduced macrophage infiltration and fibrosis in
eWAT and liver; Decreased Cd68, Ccl2, F4/80 and Saa3 gene expression in eWAT and
modulated TLR signaling pathway; Decreased plasma and serum TC, TG, FFA, VLDL-C,
LDL-C, Apo B48 and Apo B100 levels; Improved glucose tolerance and HOMA-IR index
by decreasing glucose and insulin levels; Decreased hepatic steatosis and reduced liver
TG, TC and FFA content; Reduced plasma leptin, resistin, TNF-α, MCP-1, IL-6, IL-1β,
sCD163, MIP-1β, PAI-1 and adipsin levels; Increased plasma adiponectin levels;
Decreased hepatic enzyme activity and protein expression of G6PDH, CIDEA, PPARγ,
ACC, SREBP1, SREBP2, FASN, HMGCR, ACAT, PAP, CPT, Apo B, HNF1α, HNF4α, MTP,
PEPCK and G6Pase; Increased hepatic enzyme activity of CPT and upregulated hepatic
gene expression of Pparα, Cidea, Pgc1α and Pgc1β; Increased glucokinase enzyme
activity and the protein expression of AMPK phosphorylation in the liver; Reduced
mitochondrial and cytosol H2O2, TBARS and glycogen content in the liver; Increased
hepatic SOD, CAT and GPx activities; Lowered hepatic lipotoxicity; Increased fecal
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would release hesperetin [126]. The anti-obesity properties of hesper-
idin and hesperetin have been reported in vitro and in vivo
[79,81,127–135]. In adipocyte in vitro models such as the 3T3-L1 pre-
adipocytes and hMSCs (Table 2), hesperidin and hesperetin inhibited
adipogenesis, decreased lipid and triglyceride accumulation, reduced
oxidative stress, and stimulated lipolysis [81,127–131]. Furthermore,
hesperetin was reported to stimulate cholecystokinin secretion, an ap-
petite-regulating hormone, in enteroendocrine STC-1 cells [136].
Dietary supplementation or intragastric gavage with hesperidin
(100–800 mg/kg daily for 5–12 weeks) exhibited anti-hyperlipidemic
effects in high-cholesterol diet (HCD) fed rats, Leprdb/db and HFD fed
low-density lipoprotein (LDL) receptor null (Ldlr−/−) mice, by de-
creasing plasma and hepatic FFA, triglyceride and cholesterol levels
(Table 3) [79,132,133]. Hesperidin further decreased perirenal adipose
tissue weight and reduced hepatic steatosis by decreasing the activity of
enzymes involved in cholesterol synthesis (Table 3) [79,132]. Using
Caenorhaditis elegans as an in vivo model, Peng et al. [137] reported that
hesperidin inhibits lipid accumulation by decreasing the expression of
genes involved in lipid metabolism. Similarly, hesperetin was reported
to reduce body weight gain and abdominal adipose tissue weight, and
decrease serum leptin levels in HFD fed rodents (Table 3)
[127,134,135].
Few studies evaluated the effects of hesperidin on obesity and as-
sociated metabolic disease in humans (Table 4). Administration of a
water-soluble hesperidin derivative, glucosyl hesperidin (G-hesperidin),
reduced serum triglyceride levels and improved very low-density lipo-
protein cholesterol (VLDL-C) metabolic abnormality in hyper-
triglyceridemic patients [138]. A combination of G-hesperidin and
caffeine (PubChem CID: 2519) decreased abdominal fat area and BMI in
healthy, moderately obese subjects [139]. In contrast to these studies,
consumption of pure hesperidin did not reduce serum TC and LDL-C
levels in moderately hypercholesterolemic subjects (Table 4) [140].
These studies suggest that poor bioavailabity of hesperidin compared to
its derivatives [141] may contribute to its limited bioactivity. Co-
treatment of hesperetin with trans-resveratrol (PubChem CID: 445154),
compared to the respective compounds, improved metabolic and vas-
cular health in overweight and obese subjects (Table 4) [142], sug-
gesting that the combined effects of these compounds increase their
Table 3 (continued)
Compound Experimental Model Dose and Treatment Period Experimental Outcomes and Proposed Mechanism References
Western diet fed male Ldlr−/−
C57BL/6 mice
100 mg/kg diet for 14
weeks
Reduced aortic lipid accumulation; Decreased plasma TC, TG and LDL levels; Reduced




20 and 100 mg/kg BW
daily for 8 weeks
Decreased BW gain, reduced plasma and hepatic TG levels, decreased hepatic lipid
accumulation, increased hepatic glycogen content and improved glucose tolerance;
Decreased hepatic LXRα, LXRβ, SREPB1c, FASN, SCD1, ACC1 and GPAM gene and
protein expression
[210]
Abbreviations: α-KGDH, alpha-ketoglutarate dehydrogenase; α-SMA, alpha smooth muscle actin; ABCA1, ATP binding cassette subfamily A member 1; ABCG1, ATP
binding cassette subfamily G member 1; ABCG8, ATP binding cassette subfamily G member 8; ABTS, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid);
ACADM, acyl coenzyme A dehydrogenase; ACAT, acetyl coenzyme A: cholesterol acyltransferase; ACC, acetyl coenzyme A carboxylase; ACCα, acetyl coenzyme A
carboxylase alpha; ACO, acyl coenzyme oA oxidase; ACOX1, acyl coenzyme A oxidase 1; AGE, advanced glycation end products; AKT, protein kinase B; AMPK, 5′
AMP-activated protein kinase; AMPK1α, 5′ AMP-activated protein kinase alpha 1; Apo B, apolipoprotein B; Apo B100, apolipoprotein B100; Apo B48, apolipoprotein
B48; ATGL, adipose tissue triglyceride lipase; ATP5J, ATP synthase peripheral stalk subunit F6; ATP5g1, ATP synthase lipid-binding protein mitochondrial; BAT,
brown adipose tissue; BW, body weight; CAT, catalase; CCL2, C-C motif chemokine ligand 2; CCL3, C-C motif chemokine ligand 3; CD137, tumor necrosis factor
receptor superfamily member 9; CD36, cluster of differentiation 36; CD68, cluster of differentiation 68; CE, cholesterol esters; ChREBP, carbohydrate-responsive
element-binding protein; CIDEA, cell death-inducing DNA fragmentation factor α-like effector A; CITED1, Cbp/p300-interacting transactivator 1; COXI, cytochrome c
oxidase I; COXIV, cytochrome c oxidase subunit 4 isoform 1; COX4I1, cytochrome c oxidase subunit 4I1; COX6B1, cytochrome c oxidase subunit 6B1; CPT-1,
carnitine palmitoyltransferase 1; CPT-2, carnitine palmitoyltransferase 2; Cyt-c, cytochrome 2; CYP2b9, cytochrome P450 family 2 subfamily b, polypeptide 9;
CYP3A4, cytochrome P450 family 3 subfamily A member 4; CYP7A1, cytochrome P450 family 7 subfamily A member 1; DGAT, diglyceride acyltransferase; DGAT2,
diglyceride acyltransferase 2; DHTKD1, dehydrogenase E1 and transketolase domain containing 1; ELOVL3, ELOVL fatty acid elongase 3; EMR1, EGF-like module
containing, mucin-like, hormone receptor-Like 1; eNOS, endothelial nitric oxide synthase; ER, endoplasmic reticulum; ERRα, estrogen-related receptor alpha; eWAT,
epididymal white adipose tissue; F4/80, macrophage-specific adhesion-G protein-coupled receptors E1; FA, fatty acid; FASN, fatty acid synthase; FFA, free fatty acids;
FGF21, fibroblast growth factor 21; G6Pase, glucose 6-phosphatase; G6PDH, glucose-6-phosphate dehydrogenase; GLUT4, glucose transporter 4; GPAM, glycerol-3-
phosphate acyltransferase 1 mitochondrial; GPx, glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; GST, glutathione S-transferase; H2H2, hy-
drogen peroxide; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment insulin resistance; HMGCR, 3-hydroxy-3-methylglutaryl-
coenzyme A reductase; HMG-CoA, 3-hydrox-y 3-methylglutaryl-coenzyme A; HNF1α, hepatocyte nuclear factor 1 alpha; HNF4α, hepatocyte nuclear factor 4 alpha;
Hs-CRP, high-sensitivity C-reactive protein; HSL, hormone sensitive lipase; iBAT, interscapular brown adipose tissue; ICR, imprinting control region; IDH, isocitrate
dehydrogenase 1; IL-1β, interleukin 1 beta; IL-6, interleukin 6; iNOS, inducible nitric oxide synthase; iWAT, inguinal white adipose tissue; JNK, c-Jun N-terminal
kinase; LDL-C, low-density lipoprotein cholesterol; LEPR, leptin receptor; LKB1, liver kinase B1; LOOH, lipid hydroperoxide; LPO, lipid peroxide; LPL, lipoprotein
lipase; LXRα, Liver X receptor alpha; LXRβ, Liver X receptor beta; Mac-2, macrophage marker 2; MCP-1, monocyte chemoattractant protein 1; MDA, mal-
ondialdehyde; MIP-1β, macrophage inflammatory protein 1 beta; miR-214-3p, microRNA -214-3p; mMCP-4, mast cell protease 4; mtDNA, mitochondrial deoxyr-
ibonucleic acid; mTOR, mechanistic target of rapamycin; MTP, microsomal triglyceride transfer protein; mWAT, mesenteric white adipose tissue; NEFA, non-
esterified fatty acids; NF-κB, nuclear factor kappa B; NO, nitric oxide; NRF1, nuclear respiratory factor 1; ox-LDL, oxidized low-density lipoprotein; PAI-1, plas-
minogen activator inhibitor-1; PAP, Phosphatidate phosphatase; PEPCK, phosphoenolpyruvate carboxykinase; PCK2, phosphoenolpyruvate carboxykinase 2; PGC1α,
peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC1β, peroxisome proliferator-activated receptor gamma coactivator 1 beta; pgWAT,
perigonadal white adipose tissue; PLIN2, perilipin 2; PNPLA2, patatin like phospholipase domain containing 2; PPARα, peroxisome proliferator-activated receptor
alpha; PPARγ, peroxisome proliferator-activated receptor gamma; PON, paraoxonase; pWAT, perirenal white adipose tissue; pvWAT, perivascular adipose tissue;
RBP4, retinol binding protein 4; RER, respiratory exchange ratio; ROS, reactive oxygen species; rWAT, retroperitoneum white adipose tissue; SAA, serum amyloid a;
SCD1, stearoyl-CoA desaturase-1; sCD163, soluble CD antigen 163; ScWAT, subcutaneous white adipose tissue; SDHβ, succinate dehydrogenase beta; SIRT1, sirtuin-
1; SOD, superoxide dismutase; SREBP1c, sterol regulatory element-binding protein 1c; SREBF1, sterol regulatory element-binding transcription factor 1; SREBF2,
sterol regulatory element-binding transcription factor 2; STZ, streptozotocin; TBARS, thiobarbituric acid reactive substances; TC, total cholesterol; TCA, tricarboxylic
acid; TFAM, transcription factor A mitochondrial; TG, triglycerides; TLR2, toll-like receptor 2; TNF-α, tumour necrosis factor alpha; TMEM26, transmembrane
protein 26; UCP1, uncoupling protein 1; UCP2, uncoupling protein 2; UCP3, uncoupling protein 3; VCAM-1, vascular cell adhesion molecule-1; VLDL-C, very low-
density lipoprotein cholesterol; vWAT, visceral white adipose tissue; wt, weight.
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bioactivity.
Naringenin (4′,5,7-trihydroxyflavanone) (PubChem CID: 932), an
aglycone flavanone found abundant in citrus such as grapefruit, has
been detected in honeybush extracts such as C. genistoides [143]. It is,
however, not present in detectable quantities in hot water infusions of
“fermented” C. genistoides and others [11,83]. Beelders et al. showed
the presence of naringenin derivatives in C. genistoides [120], later
identified by Danton et al. [122], as 5-[α-L-rhamnopyranosyl-(1→2)-β-
D-glucopyranosyloxy] naringenin diastereomers with the 2S-diaster-
eomer predominant, and the 2R-diastereomer formed through epimer-
ization during heating and the high temperature oxidation process
(“fermentation”) of the plant material [120,122]. Similar to hesperidin,
the release of naringenin is to be expected in the gut [144–146]. Using
in vitro adipocyte models and in vivo animal models of obesity and as-
sociated metabolic complications, several studies demonstrated the
anti-obesity and anti-inflammatory properties of naringenin (Tables 2
and 3). Naringenin was shown to inhibit adipocyte differentiation
[127,147] and TNF-α-induced lipolysis in 3T3-L1 adipocytes and
mouse primary adipocytes [148]. Other in vitro studies (Table 2) re-
ported that naringenin inhibits TNF-α-stimulated FFA and monocyte
chemoattractant protein 1 (MCP-1) secretion in adipocytes co-cultured
with macrophages, 3T3-L1 adipocytes and mouse primary adipocytes
[148–152]. Naringenin also promoted thermogenic gene expression in
human white adipose tissue [153]. In diet-induced and genetically
obese rodents, naringenin ameliorated obesity by reducing body
weight, decreasing visceral and subcutaneous adiposity, increasing
energy expenditure and attenuating adipose tissue inflammation
(Table 3) [127,151,152,154–164]. Naringenin also improved hyperli-
pidemia by decreasing circulatory and hepatic lipids, inhibiting fatty
acid synthesis and increasing fatty acid oxidation in heart, muscle and
hepatic tissues (Table 3) [127,157,165–171]. In diet-induced obese
rodents, naringenin decreased hepatic steatosis, attenuated systematic
and hepatic inflammation, reduced oxidative stress, prevented athero-
sclerosis and improved insulin sensitivity (Table 3)
[157,166,168,169,172–179]. Like naringenin, naringin (PubChem CID:
442428), one of its glycosidic form (not detected in infusions and
aqueous extracts of Cyclopia spp.), has been shown to ameliorate obe-
sity and obesity-related metabolic disturbances [180].
Eriocitrin (eriodictyol 7-O-rutinoside) (PubChem CID: 83489) has
been detected in several Cyclopia extracts [83,120,121,181]. To date,
neither in vitro nor in vivo studies reported on the anti-obesity properties
of eriocitrin in adipose tissue, however, studies have shown that this
flavonoid ameliorates obesity in other tissues and in the circulation
(Table 3). In particular, treatment with eriocitrin lowered serum lipid
profile levels in HFD and HCD fed rats [182], and suppressed HFD-
induced systemic inflammation in mice [183]. Similarly, eriocitrin re-
duced plasma triglyceride levels and hepatic steatosis in diet-induced
obese zebrafish, and this was mediated by increased mitochondrial beta
(β)-oxidation (Table 3) [184]. Correspondingly, eriocitrin is expected to
be hydrolyzed to eriodictyol (PubChem CID: 440735), its aglycone, by
Fig. 2. Summary of the effects of Cyclopia phenolic compounds on obesity and associated metabolic disease, and the major tissues modulated by Cyclopia phenolic
compounds. In this study, we speculate that the phenolic compounds of Cyclopia target BAT, increasing thermogenesis, mitochondrial energetics and energy ex-
penditure, and target WAT, preventing adipose tissue dysfunction by reducing adipocyte hypertrophy, inflammation, hypoxia, oxidative stress and excessive lipolysis,
and enhancing insulin sensitivity and the browning of white adipocytes. The anti-obesity effects of the phenolic compounds of Cyclopia in BAT and WAT, ameliorates
obesity-associated complications in the liver by reducing hyperlipidemia and cholesterol metabolism, steatosis and lipid content, inflammation, lipotoxicity and
oxidative stress, and inducing lipid oxidation, mitochondrial biogenesis and energy metabolism. In the circulation, the phenolic compounds of Cyclopia reduce
hyperlipidemia, lipid profile, inflammation, oxidative stress and insulin resistance, and improve glucose tolerance. In the muscle, the phenolic compounds of Cyclopia
decrease lipid content, oxidative stress and lipotoxicity, and induce lipid oxidation, mitochondrial biogenesis and bioenergetics, and stimulate insulin sensitivity and
glucose uptake.
Figure abbreviations: BAT, brown adipose tissue; FFAs, free fatty acids; LDL-C, low-density lipoprotein cholesterol, TC, total cholesterol; TG, triglycerides; VLDL-C,
very low-density lipoprotein cholesterol; WAT, white adipose tissue.
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intestinal bacteria [144,185]. Eriodictyol has been shown to possess
anti-diabetic, anti-inflammatory and anti-obesity properties
[183,186–190]. In HFD-fed obese mice, eriodictyol alleviated obesity
by reducing fat deposition and decreasing lipogenesis-related gene ex-
pression in white adipose tissue, thus protecting against obesity-asso-
ciated metabolic complications by reducing hepatic steatosis, de-
creasing plasma and hepatic triglyceride, TC and FFA levels, improving
insulin sensitivity, and protecting against systematic inflammation and
oxidative stress [183,189]. Our literature search did not retrieve any
clinical studies reporting on the anti-obesity effects of naringenin,
eriocitrin and eriodictyol in humans.
More recently, we identified the relative abundance of neoponcirin
(isosakuranetin-7-O-rutinoside) (PubChem CID: 16760075), also known
as didymin, in C. intermedia [16], however, the anti-obesity potential of
this flavanone or its aglycone, isosakuranetin (PubChem CID: 160481),
has not been reported to date, although studies have shown that di-
dymin prevents hyperglycemia-induced endothelial dysfunction and
inflammation, and attenuates vascular endothelial growth factor
(VEGF)-induced angiogenesis [191,192], while stimulating glucose
uptake and reducing hepatic glucose production in insulin resistant
HepG2 cells [193], demonstrating its cardioprotective and anti-diabetic
effects.
5.2.2. Flavones
Luteolin (3′,4′,5,7-tetrahydroxyflavone) (PubChem CID: 5280445),
characterized by hydroxyl moieties at positions 5, 7, 3′, and 4′ and a
2–3 carbon double bond [194], has been detected in relatively low
concentrations in Cyclopia extracts such as C. intermedia and C. sub-
ternata [16,117–119]. Scolymoside (PubChem CID: 5282152), the 7-O-
neohesperidoside of luteolin, is one of the major compounds in C.
subternata extracts [16,181]. Numerous in vitro studies have shown that
luteolin protects against obesity by decreasing lipid accumulation and
triglyceride content in 3T3-L1 adipocytes (Table 2) [131,195–200].
Luteolin also suppressed inflammation in adipocytes co-cultured with
macrophages, and in adipocytes stimulated with a macrophage-condi-
tioned media or a combination of TNF-α, LPS and interferon gamma
(IFN-γ) [201–203]. In brown and subcutaneous primary adipocytes,
luteolin increased the expression of thermogenic and beige cell gene
markers and activated the 5′ AMP-activated protein kinase/peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (AMPK/
PGC1α) signaling (Table 2) [204]. In HFD-induced obese mice, dietary
supplementation with luteolin decreased body weight, reduced adipo-
cyte hypertrophy in epididymal adipose tissue, increased energy ex-
penditure and induced thermogenesis, activated browning in sub-
cutaneous adipose tissue, suppressed adipose tissue inflammation, and
stimulated insulin sensitivity by activating AMPK-alpha 1 (AMPKα1)
signaling (Table 3) [204–207]. These studies suggest that AMPK sig-
naling might be an important target for luteolin in adipose tissues.
Further in vivo studies (Table 3) reported that luteolin alleviates obe-
sity-associated metabolic disorders such as hyperlipidemia, hepatic
steatosis and cardiovascular dysfunction in HFD fed and Leprdb/db mice
[208–213]. Our literature search could not identify any studies re-
porting on the anti-obesity potential of luteolin in humans. The anti-
obesity properties of scolymoside have not been reported yet, although
this flavone was shown to inhibit high-glucose, LPS, polyphosphate and
transforming growth factor β-induced protein (TGFBIp)-induced vas-
cular inflammation [214–217]. Vicenin-2 (apigenin 6,8-di-C-β-D-glu-
copyranoside) (PubChem CID: 442664) is a C-glycosyl flavone detected
in C. subternata, C. genistoides, C. longifolia, C. maculata and C. intermedia
extracts [16,83,120,181]. Although its anti-obesity properties have not
been reported, vicenin-2 has anti-diabetic [218,219] and anti-in-
flammatory [214–217] effects.
5.2.3. Dihydrochalcones
The two dihydrochalcones, phloretin-3′,5′-di-C-β-D-glucoside and 3-
hydroxy-phloretin-3′,5′-di-C-hexoside, are present in C. subternata, C.
maculata and C. genistoides [11,83,120,121,124,181]. Our literature
search did not retrieve any studies reporting on the anti-obesity prop-
erties of these Cyclopia dihydrochalcones, although these compounds
have been identified in high concentration in extracts of some Cyclopia
spp. Interestingly, the dihydrochalcones are very similar to aspalathin
(PubChem CID: 16752601), a C-glucosyl dihydrochalcone with mod-
ulatory effects against insulin resistance [220,221]. Aspalathin, unique
to Aspalathus species, another endemic South African plant genus, more
commonly known for rooibos (Aspalathus linearis), has been shown to
improve lipid and glucose metabolism in insulin resistant adipocytes
[220]. The anti-obesity properties of other dihydrochalcones not pre-
sent in Cyclopia, such as phloridzin (phloretin-2′-β-D-glucopyranoside)
(PubChem CID: 6072) and its aglycone, phloretin [222] (PubChem CID:
4788), are extensively reported [223–229]. In HFD-fed mice, phloridzin
decreased body weight and fat mass by alleviating lipid metabolism and
glucose homeostasis, increasing brown adipose tissue activity, and up-
regulating the expression of proteins involved in brown adipose tissue
thermogenesis [227], while both phloretin and phloridzin prevented
obesity, attenuated adipose tissue inflammation and fibrosis, and re-
duced insulin resistance and hepatic steatosis in HFD-induced obese
mice [223,225,229]. Phloretin and phloridzin also decreased lipid ac-
cumulation by stimulating lipolysis in 3T3-L1 adipocytes, and sup-
pressed inflammation by reducing nitrite and pro-inflammatory cyto-
kine secretion levels in TNF-α-induced 3T3-L1 adipocytes, in 3T3-L1
adipocytes co-cultured with macrophages and in macrophages induced
with adipocyte-conditioned media [226]. Thus, the anti-obesity po-
tential of Cyclopia dihydrochalcones warrants further investigation.
5.3. Benzophenones
Benzophenones are a class of natural compounds abundant in plants
such as the Clusiaceae family [230], but recently, the C-glucosyl ben-
zophenones, 3-β-D-glucopyranosyliriflophenone, 3-β-D-glucopyranosyl-
4-β-D-glucopyranosyloxyiriflophenone and 3-β-D-glucopyr-
anosylmaclurin have been detected in several Cyclopia extracts
[83,120,124,125,231–234]. In vitro studies reporting on the anti-obe-
sity potential of Cyclopia benzophenones are limited (Table 2), while
there is currently no in vivo animal and human studies that have re-
ported on the anti-obesity potential of these benzophenones. Zhang
et al. [235–237] reported that 3-β-D-glucopyranosyliriflophenone and
3-β-D-glucopyranosylmaclurin decreased lipid accumulation, trigly-
ceride content and FFA accumulation in 3T3-L1 adipocytes (Table 2). In
addition, 3-β-D-glucopyranosyl-4-β-D-glucopyranosyloxyiriflophenone
and 3-β-D-glucopyranosyliriflophenone marginally increased glucose
uptake in 3T3-L1 adipocytes and C3A hepatocytes [231], while 3-β-D-
glucopyranosyliriflophenone lowered fasting blood glucose levels in
diabetic mice and enhanced glucose uptake in cultured adipocytes de-
rived from white epididymal fat pads [238], demonstrating their anti-
diabetic potential.
6. Cyclopia as a source of phenolic compounds exhibiting
potential anti-obesity bioactivity
The studies included in this review suggest that the anti-obesity
properties of Cyclopia extracts may be attributed to their phenolic
constituents, but whether a single compound or combinatorial effects as
a result of the complex mixture of polyphenols, or other extract con-
stituents such as pinitol (PubChem CID: 164619), could be responsible
for the anti-obesity potential of Cyclopia, are still to be elucidated.
Pinitol is a cyclitol compound, occurring in Cyclopia spp. [117,119].
This compound showed anti-inflammatory effects in human obesity by
reducing the circulating levels of IL-6 and TNF-α, increasing sirtuin-1
(SIRT1) expression in peripheral blood mononuclear cells, and reducing
the expression of IL-6, TNF-α, and the endoplasmic reticulum stress
markers in subcutaneous white adipose tissue [239]. Using high per-
formance counter-current chromatography (HPCCC) to separate the
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crude polyphenol-enriched fraction (CPEF) of C. intermedia into four
major sub-fractions, we demonstrated that fractionation does not en-
hance activity within a single fraction, but rather that all the sub-
fractions exhibited anti-obesity effects, suggesting that the anti-obesity
potential of C. intermedia is attributed to more than one phenolic
compound [17]. Furthermore, the anti-obesity effects of the CPEF of C.
intermedia were greater compared to the HPCCC sub-fractions, sug-
gesting potential combinatorial effects between phenolic constituents
[16,17].
Generally, polyphenols are known to have poor bioavailability, due
to their low absorption in the human gastrointestinal (GI) tract, rapid
biotransformation in the gut and liver and excretion from the body
[240]. Several factors, including the chemical structure, molecular
weight, low stability or the gastrointestinal environment contribute to
poor bioavailabity of phenolic compounds [241]. For example, man-
giferin has low bioavailabity, due to its sugar glucoside that is directly
attached to the aglycone by the CeC bond, making it more resistant to
acid and enzyme hydrolysis [107,242–245]. Other studies reported
increased bioavailability of mangiferin, when administered with a
herbal formulation [246] or with absorption enhancers such as sodium
deoxycholate (PubChem CID: 23668196) and Carbopol 974P (PubChem
CID: 8314) [247]. Similarly, studies have shown that hesperidin is
poorly absorbed in its glycoside form due to the attached rutinoside
moiety that requires hydrolysis, most likely by bacterial intestinal en-
zymes, before being absorbed in its aglycone form (hesperetin) and
further metabolized in the intestinal epithelium and liver [248,249].
Poor bioavailability of hesperidin is also attributed to its low water
solubility, hence a water-soluble derivative of hesperidin, G-hesperidin,
with similar metabolic profile as hesperidin, was absorbed more rapidly
and efficiently than hesperidin in rats [141]. Similarly, α-monoglucosyl
hesperidin increased energy expenditure by stimulating the formation
of brown-like adipocytes and inducing thermogenesis in mouse inguinal
white adipose tissue (iWAT), while hesperidin was not effective [250].
In line with this, the metabolites of mangiferin and hesperidin, nor-
athyriol and hesperetin, were absorbed from the gastrointestinal tract
of pigs after an oral administration of a C. genistoides extract [251], and
high hesperetin levels were detected in the liver and aorta of rats after
consuming a hesperetin-containing diet for 4 weeks, suggesting that the
aorta is one of the main target tissues of hesperetin for exerting its
functions [252]. The solubility and bioavailability of naringenin is also
reported to be low, and this is attributed to its largely hydrophobic ring
structure [253]. Co-treatment with the excipient, hydroxypropyl-β-cy-
clodextrin (PubChem CID: 14049689), enhanced the solubility and
bioavailability of naringenin and ameliorated dyslipidemia and dia-
betes in rats [254]. Naringenin was detected in human plasma after
consumption of a meal containing cooked tomato paste [255], sug-
gesting its bioavailability when consuming tomato-containing food.
Thus, further studies into the bioavailability and mechanism of action
of Cyclopia phenolic compounds are essential for developing anti-obe-
sity agents that efficiently target and reach the site of action.
To date, the human studies examining the effects of Cyclopia ex-
tracts focused on the skin [256,257] and no other clinical or human
studies, including an investigation of their anti-obesity potential, have
been reported thus far. There are also no significant side effects re-
ported for honeybush tea consumption by humans [258]. The wide-
spread use of herbal medicines and natural compounds, especially in
quantities much higher than normally consumed through the diet, have
led to increasing, but valid concerns about their safety and toxicity in
view of adverse biological and hepatotoxic effects of some products
[259–262]. The information regarding the safety and toxicity of hon-
eybush tea consumption, either as herbal tea or extract containing high
levels of specific compounds, is very limited. A pre-clinical study by van
der Merwe and colleagues [263] assessed the possible hepatoxicity and
oxidative effects of polyphenol-enriched extracts of C. genistoides and C.
subternata following short-term (28 days) and sub-chronic (90 days)
dietary treatment of Fischer 344 rats. The authors reported that
although these extracts exhibited limited adverse effects, they altered
the expression of anti-oxidant defense and oxidative stress-related
genes in the liver of rats, suggesting that dose and duration of exposure
to the extracts should be monitored carefully [263]. Similarly, treat-
ment of Fischer 344 rats with aqueous extracts prepared from fer-
mented and unfermented C. intermedia had no significant effect on the
activities of the liver function enzymes, aspartate transaminase (AST),
alanine transaminase (ALT) and alkaline phosphatase (ALP) [264].
Further studies are required to evaluate the potential adverse effects of
honeybush tea consumption, particularly its hepatoxic effects.
Cyclopia extracts contain a complex mixture with more than one
active compound, thus increasing the possibility of herb-drug interac-
tions, especially in patients taking chronic medications [265]. Herb-
drug interactions can adversely affect drug metabolism, by either de-
creasing or increasing the concentration of a drug in a specific tissue,
consequently inducing toxicity or reducing the efficacy of the drug
treatment. Currently there are no studies reporting on any herb-drug
interactions between Cyclopia extracts and the conventional drugs, al-
though the phenolic compounds of Cyclopia have been reported to
modulate drug metabolizing enzymes or interact with conventional
drugs. The flavonoids, luteolin and naringenin, inhibit the activity of
cytochrome P450 family 3 subfamily A member 4 (CYP3A4)
[266–268], the main enzyme involved drug metabolism in the liver and
gut [269]. An in vivo pharmacodynamic study showed that naringenin
interferes with the anti-diabetic actions of pioglitazone (PubChem CID:
4829) [270], while the anti-diabetic activity of mangiferin was im-
proved in combination with the hypoglycemic drugs, metformin (Pub-
Chem CID: 4091) and gliclazide (PubChem CID: 3475) [271]. Fur-
thermore, hesperidin was responsible for the decreased intestinal
absorption of celiprolol (beta-blocker) (PubChem CID: 42373), an anti-
hypertensive drug, in rats [272].
7. Summary and conclusions
In the current paper, we systematically reviewed studies reporting
on the anti-obesity properties of Cyclopia extracts and their major
phenolic compounds, classified as xanthones, flavonoids and benzo-
phenones. Extracts from C. maculata, C. intermedia and C. subternata
were reported to inhibit adipogenesis, decrease lipid accumulation,
stimulate lipolysis, and decrease body weight gain in Leprdb/db mice,
however, their mechanism of action is not yet fully elucidated. The anti-
obesity properties of several Cyclopia phenolic compounds, common to
other plants, are widely reported. These compounds improve lipid
metabolism, induce thermogenesis, ameliorate oxidative stress, and
reduce insulin resistance and inflammation in vitro, in adipocyte models
(Fig. 2). In in vivo models, these compounds were shown to reduce
obesity by decreasing body weight and adiposity, increasing energy
expenditure, and promoting satiety (Fig. 2). Furthermore, they at-
tenuate obesity-associated metabolic complications such as hyperlipi-
demia, hepatic steatosis, insulin resistance and cardiometabolic dis-
orders in peripheral tissues (Fig. 2). Clinical studies reporting on the
anti-obesity potential of Cyclopia phenolic compounds in humans are
limited, and only mangiferin, hesperidin and hesperetin were tested in
human studies, showing that they decreased body weight and adiposity,
reduced inflammation and blood glucose levels, and improved hy-
perlipidemia and vascular function (Fig. 2). However, these studies
were either contradictory, or the phenolic compounds were used in
combination with other compounds, or a modified soluble form or
derivative of the compounds were used. Additional translational studies
from animals to humans are needed to further confirm the anti-obesity
benefits of Cyclopia and its phenolic compounds. Our literature search
did not retrieve any studies reporting on the anti-obesity properties of
the dihydrochalcones, phloretin-3′,5′-di-C-β-D-glucoside and 3-hydroxy-
phloretin-3′,5′-di-C-hexoside, although these compounds have been
identified in substantial quantities in extracts of some Cyclopia spp. The
xanthone, isomangiferin, the flavanone, neoponcirin and the flavones,
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scolymoside and vicenin-2, were reported to only ameliorate obesity-
associated metabolic conditions. Furthermore, norathyriol, hesperetin,
eriodictyol and naringenin, aglycone metabolites of mangiferin, he-
speridin, eriocitrin and naringenin glycosides, respectively, also exerted
anti-obesity activities in vitro and in vivo. In conclusion, this review
demonstrates that Cyclopia is a potential source of anti-obesity com-
pounds with adipose tissue as the potential therapeutic target of these
compounds, thus providing motivation for further studies to elucidate
mechanisms and underscore the development of honeybush-derived
anti-obesity nutraceuticals.
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